Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
genetic diseases
Biotech
Harmony halts genetic disease program after phase 3 failure
After its cannabidiol gel failed a phase 3 trial in fragile X syndrome, Harmony has paused development of the asset in a different genetic disease.
Darren Incorvaia
Nov 4, 2025 12:45pm
BridgeBio's calcium deficiency candidate scores phase 3 win
Oct 29, 2025 7:00am
Chiesi fertilizes Arbor's gene therapy with $2B biobucks deal
Oct 6, 2025 7:00am
Servier supercharges neuro pipeline with $450M deal
Sep 8, 2025 2:30am
Wave reports AATD win, but investors lukewarm
Sep 3, 2025 3:00pm
RNA biotech emerges with $52M and clinical rare disease asset
Aug 25, 2025 10:13am
